Evidence-based Medicine
Trusting evidence over anecdote: Clinical decision making in the era of Covid-19
24 Jul, 2020 | 09:29h | UTCTrusting evidence over anecdote: Clinical decision making in the era of covid-19 – The BMJ Opinion
How to understand COVID-19 numbers
23 Jul, 2020 | 08:32h | UTCHow to Understand COVID-19 Numbers – ProPublica
The best time to argue about what a replication means? Before you do it
23 Jul, 2020 | 08:20h | UTCThe best time to argue about what a replication means? Before you do it – Nature
Editorial: The RECOVERY platform
22 Jul, 2020 | 02:37h | UTCThe RECOVERY Platform – New England Journal of Medicine
How (not) to write about global health
21 Jul, 2020 | 09:05h | UTCHow (not) to write about global health – The BMJ Global Health
Related Commentary on Twitter
Great satirical article on the ethics of global health research collaboration and the common faux pas by @desmondtanko #globalhealth #ethics https://t.co/foOcXnK1FY
— Rennie Qin (@RennieQin) July 20, 2020
Editorial: research in the context of a pandemic
20 Jul, 2020 | 08:16h | UTCResearch in the Context of a Pandemic – New England Journal of Medicine
Related Commentary on Twitter
"Research in the Context of a Pandemic," an editorial by H. Clifford Lane, MD, and Anthony Fauci, MD, now available. #COVID19 #SARSCoV2
— NEJM (@NEJM) July 18, 2020
Covid-19: experts criticize claim that remdesivir cuts death rates
16 Jul, 2020 | 08:31h | UTCCovid-19: Experts criticise claim that remdesivir cuts death rates – The BMJ
Related Commentary on Twitter
Experts have criticised pharmaceutical firm Gilead Sciences after it released data suggesting that its antiviral drug remdesivir can reduce death rates for patients with covid-19. They say the research is intrinsically flawed @MartinLandray https://t.co/a1q2FxMa7C
— The BMJ (@bmj_latest) July 14, 2020
Evidence-based practice for public health emergency preparedness and response
15 Jul, 2020 | 08:23h | UTC
How scientific societies are weathering the pandemic’s financial storm
15 Jul, 2020 | 08:20h | UTCHow scientific societies are weathering the pandemic’s financial storm – Nature
CHEST Supplement: an overview of study design and statistical considerations
15 Jul, 2020 | 08:18h | UTCHomepage: An Overview of Study Design and Statistical Considerations – CHEST
- Introduction
- Statistical Analysis and Reporting Guidelines for CHEST
- Sample Size Estimation in Clinical Research: From Randomized Controlled Trials to Observational Studies
- Using Causal Diagrams to Improve the Design and Interpretation of Medical Research
- A Framework for the Evaluation of Statistical Prediction Models
- A Practical Overview and Reporting Strategies for Statistical Analysis of Survival Studies
- Considerations for Reporting and Reviewing Studies Including Health-Related Quality of Life
- A Practical Overview of Case-Control Studies in Clinical Practice
- Cross-Sectional Studies: Strengths, Weaknesses, and Recommendations
- Cohort Studies: Design, Analysis, and Reporting
- Randomized Controlled Trials
- Economic Evaluation Studies
- Meta-Analysis
- Studies of Medical Tests: Design and Analytical Considerations
- A Bioinformatics Crash Course for Interpreting Genomics Data
Viewpoint: communicating science in the time of a pandemic
14 Jul, 2020 | 08:28h | UTCCommunicating Science in the Time of a Pandemic – JAMA
Evidence-based medicine and COVID-19: what to believe and when to change
14 Jul, 2020 | 08:16h | UTC
A Conversation with John Ioannidis
10 Jul, 2020 | 09:43h | UTCA Conversation with John Ioannidis – The Health Care Blog
Related: Opinion: John Ioannidis and Medical Tribalism in the Era of Covid-19 – Undark AND The Totality of the Evidence – Boston Review
Related Commentary on Twitter
My candid conversation with John Ioannidis about the COVID-19 pandemic, his views and misrepresentation of his views https://t.co/FZA2OQ1H9F
— Saurabh Jha (@RogueRad) July 9, 2020
Covid-19: The Inside Story of the RECOVERY Trial
9 Jul, 2020 | 09:27h | UTCCovid-19: The inside story of the RECOVERY trial – The BMJ
Data Show Panic and Disorganization Dominate the Study of Covid-19 Drugs
7 Jul, 2020 | 09:02h | UTCData show panic and disorganization dominate the study of Covid-19 drugs – STAT
Related: Waste in covid-19 research – The BMJ AND Too much information, too little evidence: is waste in research fuelling the covid-19 infodemic? – The BMJ AND Urgent call for greater multilateralism and coordination of covid-19 trials – The BMJ
Study Publications Must Be Up-To-Date in Covid Time (Regarding the Latest Observational Hydroxychloroquine Study)
6 Jul, 2020 | 09:00h | UTCStudy Publications Must Be Up-To-Date in Covid Time – Absolutely Maybe Blog, by Hilda Bastian
Opinion – One U.K. Trial is Transforming COVID-19 Treatment. Why Haven’t Others Delivered More Results?
6 Jul, 2020 | 08:58h | UTCStudy 1 – lopinavir-ritonavir: No clinical benefit from use of lopinavir-ritonavir in hospitalised COVID-19 patients studied in RECOVERY
Study 2 – dexamethasone: Low-cost dexamethasone reduces death by up to one third in hospitalised patients with severe respiratory complications of COVID-19 – Recovery Trial AND Effect of Dexamethasone in Hospitalized Patients with COVID-19: Preliminary Report – medRxiv
Study 3 – hydroxychloroquine: No clinical benefit from use of hydroxychloroquine in hospitalised patients with COVID-19
WHO Discontinues Hydroxychloroquine and Lopinavir/Ritonavir Treatment Arms for COVID-19
6 Jul, 2020 | 09:02h | UTCCommentary: WHO says trials show malaria and HIV drugs don’t cut Covid-19 hospital deaths – The Guardian
Related Commentary on Twitter
WHO accepted the recommendation from the Solidarity Trial’s International Steering Committee to discontinue the trial’s hydroxychloroquine and the lopinavir/ritonavir arms.
More https://t.co/dCxHqBIwtr#COVID19 #coronavirus
— World Health Organization (WHO) (@WHO) July 4, 2020
Accelerating Development of SARS-CoV-2 Vaccines — The Role for Controlled Human Infection Models
2 Jul, 2020 | 08:49h | UTCRelated: Challenge Trials—Could Deliberate Coronavirus Exposure Hasten Vaccine Development? – JAMA AND Opinion: Ethical Guidelines for Deliberately Infecting Volunteers with COVID-19 to Speed Vaccine Development (commentaries on the subject) AND Feasibility, potential value and limitations of establishing a closely monitored challenge model of experimental COVID-19 infection and illness in healthy young adult volunteers – World Health Organization (draft document for public comments) AND Human Challenge Studies to Accelerate Coronavirus Vaccine Licensure – The Journal of Infectious Diseases AND Ethics of controlled human infection to address COVID-19 – Science AND Extraordinary diseases require extraordinary solutions – Vaccine
Opinion: The Moral Imperative to Include Pregnant Women in Clinical Trials of Interventions for COVID-19
2 Jul, 2020 | 08:46h | UTC
The Ethics of COVID-19 Treatment Studies: Too Many are Open, Too Few are Double-masked
2 Jul, 2020 | 08:43h | UTCThe ethics of COVID-19 treatment studies: too many are open, too few are double-masked – CEBM Oxford
Editorial: Will COVID-19 be Evidence-based Medicine’s Nemesis?
1 Jul, 2020 | 07:58h | UTCWill COVID-19 be evidence-based medicine’s nemesis? – PLOS Medicine
“In the current fast-moving pandemic, where the cost of inaction is counted in the grim mortality figures announced daily, implementing new policy interventions in the absence of randomized trial evidence has become both a scientific and moral imperative.”
Related Commentary on Twitter
https://twitter.com/trishgreenhalgh/status/1278069554640543747
Opinion: Cognitive Bias and Public Health Policy During the COVID-19 Pandemic
30 Jun, 2020 | 07:48h | UTCCognitive Bias and Public Health Policy During the COVID-19 Pandemic – JAMA
Opinion: Solve the “Medicine by Press Release” Problem with Registered Reports
29 Jun, 2020 | 09:06h | UTCSolve the “medicine by press release” problem with registered reports – Medium
Related: Science by press release: When the story gets ahead of the science – CNN
Editorial: Evaluation and Peer Review During a Pandemic
29 Jun, 2020 | 09:13h | UTCEditorial Evaluation and Peer Review During a Pandemic: How Journals Maintain Standards – JAMA